Announcements Trials

Browse Landscape

Phase

Phase 1/2 9 Phase 1 8 Phase 2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 26 Melanoma 24 Carcinoma, Renal Cell 15 Stomach Neoplasms 9 Lung Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 6 Kidney Neoplasms 5 Carcinoma, Hepatocellular 5 Brain Neoplasms 5 Urinary Bladder Neoplasms 4 Mesothelioma 4 Adenocarcinoma Of Esophagus 4 Skin Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Anus Neoplasms 3 Various Advanced Cancer 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Mesothelioma, Malignant 2 Liver Neoplasms 2 Hodgkin Disease 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Anal Canal Carcinoma 2 Adenocarcinoma 2 von Hippel-Lindau Disease 1 Uveal Melanoma 1

Interventions

Quality of Life 1 Patient Readmission 1 Palliative Care 1 Olanzapine 1 Nivolumab 1 Needs Assessment 1 Coping Skills 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Advanced Cancer × Nivolumab × Clear all

NCT02743494 2025-11-18

CheckMate 577

Bristol-Myers Squibb

Phase 3 Completed

794 enrolled 13 charts 1 FDA

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡